Literature DB >> 1531176

Energy dependence of chloroquine accumulation and chloroquine efflux in Plasmodium falciparum.

D J Krogstad1, I Y Gluzman, B L Herwaldt, P H Schlesinger, T E Wellems.   

Abstract

Chloroquine inhibits the growth of susceptible malaria parasites at low (nanomolar) concentrations because of an energy-requiring drug-concentrating mechanism in the parasite secondary lysosome (food vacuole) which is dependent on the acidification of that vesicle. Chloroquine resistance results from another energy-requiring process: efflux of chloroquine from the resistant parasite with a half-time of 2 min. Chloroquine efflux is inhibited reversibly by the removal of metabolizable substrate (glucose); it is also reduced by the ATPase inhibitor vanadate. These results suggest that chloroquine efflux is an energy-requiring process dependent on the generation and hydrolysis of ATP. Chloroquine efflux cannot be explained by differences in drug accumulation between chloroquine-susceptible and -resistant parasites because the 40-50-fold difference in initial efflux rates between -susceptible and -resistant parasites is unchanged when both parasites contain the same amount of chloroquine. Although chloroquine efflux is phenotypically similar to the efflux of anticancer drugs from multidrug-resistant (mdr) mammalian cells, it is not linked to either of the mdr-like genes of the parasite.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1531176     DOI: 10.1016/0006-2952(92)90661-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  20 in total

Review 1.  Transporters involved in resistance to antimalarial drugs.

Authors:  Stephanie G Valderramos; David A Fidock
Journal:  Trends Pharmacol Sci       Date:  2006-09-25       Impact factor: 14.819

Review 2.  Metabolomics and malaria biology.

Authors:  Viswanathan Lakshmanan; Kyu Y Rhee; Johanna P Daily
Journal:  Mol Biochem Parasitol       Date:  2010-10-21       Impact factor: 1.759

3.  Differences in trans-stimulated chloroquine efflux kinetics are linked to PfCRT in Plasmodium falciparum.

Authors:  Cecilia P Sanchez; Petra Rohrbach; Jeremy E McLean; David A Fidock; Wilfred D Stein; Michael Lanzer
Journal:  Mol Microbiol       Date:  2007-04       Impact factor: 3.501

4.  Dictyostelium discoideum expresses a malaria chloroquine resistance mechanism upon transfection with mutant, but not wild-type, Plasmodium falciparum transporter PfCRT.

Authors:  Bronwen Naudé; Joseph A Brzostowski; Alan R Kimmel; Thomas E Wellems
Journal:  J Biol Chem       Date:  2005-05-09       Impact factor: 5.157

5.  In vitro antimalarial activity of a new organometallic analog, ferrocene-chloroquine.

Authors:  O Domarle; G Blampain; H Agnaniet; T Nzadiyabi; J Lebibi; J Brocard; L Maciejewski; C Biot; A J Georges; P Millet
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX.

Authors:  Patrick G Bray; Mathirut Mungthin; Ian M Hastings; Giancarlo A Biagini; Dauda K Saidu; Viswanathan Lakshmanan; David J Johnson; Ruth H Hughes; Paul A Stocks; Paul M O'Neill; David A Fidock; David C Warhurst; Stephen A Ward
Journal:  Mol Microbiol       Date:  2006-08-31       Impact factor: 3.501

7.  Antimalarial activity of thiosemicarbazones and purine derived nitriles.

Authors:  Jeremy P Mallari; Wendyam A Guiguemde; R Kiplin Guy
Journal:  Bioorg Med Chem Lett       Date:  2009-05-05       Impact factor: 2.823

Review 8.  [Malaria--biological aspects of an infectious disease of importance to humans].

Authors:  J P Hildebrandt
Journal:  Naturwissenschaften       Date:  1996-08

9.  Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.

Authors:  Amar Bir Singh Sidhu; Dominik Verdier-Pinard; David A Fidock
Journal:  Science       Date:  2002-10-04       Impact factor: 47.728

10.  No seasonal accumulation of resistant P. falciparum when high-dose chloroquine is used.

Authors:  Johan Ursing; Poul-Erik Kofoed; Amabelia Rodrigues; Lars Rombo
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.